Patients

Giving patients a chance is what drives us. We are committed to developing safe and effective therapies for those suffering of a wide range of fibrotic diseases.

Pliant is currently targeting fibrotic diseases in a variety of organs and conditions, including the lung (IPF), liver (primary sclerosing cholangitis, NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma) and the gastrointestinal tract (stricturing Crohn’s disease).

With biomarker-based approaches, Pliant aims to design efficient clinical trials leveraging validated clinical endpoints and potentially improve diagnosis, selection and assessment of treatments for IPF.

IPF Patient Registry and Biomarker Registry

Pliant has dedicated resources to building a robust patient registry. Through our collaborations with UCSF and Stanford University, we are collecting clinical and laboratory data on patients with IPF. Our registry aims to expand knowledge of the natural progression of the disease and fuel biomarker discovery.

Despite significant study, currently no validated biomarkers exist for IPF, but Pliant is working to change that. Our biomarker discovery efforts seek to identify and validate proteins or genes that can be used for early diagnosis, risk stratification, predicting response to therapy, and monitoring response to therapy. Pliant scientists and research collaborators have successfully integrated tissue and plasma proteomics approaches to enhance detection of tissue-specific and circulating proteins related to fibrotic lung disease.

Clinical Trial Access

We are eager to initiate clinical development of our lead product candidate, PLN-74809, in early 2019 as a potential treatment option for patients with IPF.

IPF is a chronic and progressive fibrotic disease in which lung tissue becomes thickened, stiff and scarred, leading to increased difficulty in breathing and decreased quality of life. As lung fibrosis progresses, it becomes increasingly difficult for the lungs to transfer oxygen into the bloodstream— ultimately preventing vital organs from receiving the oxygen necessary to function properly. IPF currently affects approximately 140,000 people in the U.S.

If you are interested in learning more about this clinical trial, email us at info@pliantrx.com.

IPF currently affects approximately

140,000

people in the U.S.